Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity
Go back to Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 39.43 +0.37 (0.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $39.06 | 52 Week High | $59.00 | |||
| Open | $39.39 | 52 Week Low | $32.80 | |||
| Day High | $39.77 | P/E | N/A | |||
| Day Low | $39.24 | EPS | $0.00 | |||
| Volume | 8,556,398 | |||||



